# US Selumetinib Registry

> **NCT05683678** · — · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Neurofibromatosis Type 1
- Plexiform Neurofibromas

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05683678
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-04
- **Primary completion:** 2024-11-13
- **Final completion:** 2024-11-13
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05683678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05683678, "US Selumetinib Registry". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05683678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*